Lyra Therapeutics, Inc. (LYRA) Key Metrics
LYRA valuation today
Trailing 12 months · as of October 21, 2026- Market cap
- $337,227
- Enterprise value
- $14.7M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 0.8
- Price / book
- 7.1
- EV / EBITDA
- 0.7
- Dividend yield
- —
- Beta
- 0.50
LYRA key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsLYRA returns How much profit the business earns on the capital it uses.
LYRA financial health Debt, liquidity and how easily interest is covered.
LYRA efficiency & capital use Working capital cycle and where the cash goes.
LYRA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
LYRA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
LYRA key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Per share | ||||||||
| Revenue per share | — | — | — | — | — | $0.00 | $0.00 | $0.20 |
| Earnings per share | — | — | — | — | — | −$2.58 | −$1.99 | −$0.96 |
| Operating cash flow per share | — | — | — | — | — | −$2.46 | −$1.68 | −$1.06 |
| Free cash flow per share | — | — | — | — | — | −$2.67 | −$1.71 | −$1.07 |
| Cash per share | — | — | — | — | — | $8.68 | $1.20 | $3.81 |
| Book value per share | — | — | — | — | — | $8.67 | $0.90 | −$17.09 |
| Tangible book value per share | — | — | — | — | — | $8.67 | $0.90 | −$17.09 |
| Capex per share | — | — | — | — | — | $0.21 | $0.03 | $0.01 |
| Debt per share | — | — | — | — | — | $0.28 | $0.41 | — |
| Shares outstanding | — | — | — | — | — | 8.6M | 8.2M | 6.3M |
| Change in shares outstanding | — | — | — | — | — | +5.0% | +30.6% | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | — | −185.0% | −73.7% | −96.1% | −78.0% | −54.1% | — | — |
| Return on invested capital (ROIC) | −541.8% | −803.5% | — | — | — | — | — | — |
| Return on assets (ROA) | −56.5% | −89.4% | −49.6% | −67.1% | −62.5% | −46.2% | −80.9% | −23.8% |
| Return on tangible assets | −80.1% | −140.8% | −44.0% | −50.3% | −77.3% | −27.4% | −109.0% | −23.8% |
| Free cash flow margin | — | — | — | — | — | — | — | −536.7% |
| Financial health | ||||||||
| Total debt | $30.3M | $34.4M | $26.9M | $4.2M | $1.5M | $2.4M | $3.3M | — |
| Cash & short-term investments | $15.9M | $40.6M | $102.8M | $97.9M | $45.7M | $74.6M | $9.8M | $23.9M |
| Net debt | $14.4M | −$6.2M | −$75.9M | −$93.7M | −$44.3M | −$72.2M | −$6.5M | −$23.9M |
| Debt / equity | — | 2.97 | 0.30 | 0.05 | 0.04 | 0.03 | 0.45 | — |
| Debt / assets | 0.84 | 0.52 | 0.19 | 0.04 | 0.03 | 0.03 | 0.22 | — |
| Current ratio | 1.71 | 3.41 | 5.35 | 6.97 | 2.63 | 15.54 | 1.94 | 12.72 |
| Quick ratio | 1.71 | 3.41 | 5.35 | 6.97 | 2.63 | 15.54 | 1.94 | 12.72 |
| Interest coverage | — | — | — | -107.5 | -427.6 | -270.8 | -77.6 | -5.9 |
| Working capital | $6.8M | $30.4M | $85.2M | $86.4M | $29.7M | $71.0M | $4.9M | $23.0M |
| Invested capital | $3.6M | $5.4M | $13.5M | −$13.0M | −$10.0M | $2.3M | $846,000 | −$131.0M |
| Tangible asset value | −$10.7M | $11.6M | $89.4M | $80.8M | $34.3M | $74.5M | $7.3M | −$107.1M |
| Net current asset value | −$30.6M | −$11.7M | $51.6M | $71.6M | $27.4M | $69.6M | $2.5M | −$107.5M |
| Graham net-net per share | — | — | — | — | — | $7.95 | $0.27 | −$17.30 |
| Capital allocation | ||||||||
| Share buybacks (net) | — | — | — | — | — | $0 | $0 | $0 |
| Capex / revenue | 29.1% | 152.4% | 67.2% | 12.0% | 1,187.7% | — | — | 3.0% |
| Capex / depreciation | 0.25 | 4.96 | 3.77 | 0.15 | 3.38 | 18.68 | 7.81 | 0.45 |
| Stock-based compensation / revenue | 586.7% | 437.8% | 377.9% | 399.6% | 971.9% | — | — | 32.6% |
| R&D / revenue | 4,625.9% | 2,853.1% | 3,082.7% | 2,846.4% | 10,418.9% | — | — | 399.9% |
| SG&A / revenue | 2,899.5% | 1,206.1% | 1,223.2% | 1,288.0% | 4,984.6% | — | — | 283.6% |
| Efficiency | ||||||||
| Days sales outstanding | — | — | — | — | — | — | — | 49.0 |
| Days payables outstanding | — | 1,670.0 | 21.8 | 981.9 | 737.8 | 29.0 | 11,490.7 | — |
| Receivables turnover | — | — | — | — | — | — | — | 7.45 |
| Payables turnover | 0.00 | 0.22 | 16.71 | 0.37 | 0.49 | 12.58 | 0.03 | 0.00 |
| Inventory turnover | — | — | — | — | — | — | — | 0.00 |
| Asset turnover | 0.01 | 0.01 | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 | 0.05 |
| Average receivables | — | — | — | — | — | — | — | $167,000 |
| Average payables | $921,000 | $2.2M | $2.9M | $2.9M | $2.0M | $995,500 | $850,000 | $631,000 |
| Average inventory | — | — | — | — | — | — | — | $1 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from LYRA's annual financial statements (latest annual report filed March 31, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
LYRA valuation and financial ratios
Lyra Therapeutics earned a return on invested capital of −541.8% in fiscal 2025. It ended the year with $30.3 million of debt and $15.9 million in cash and short-term investments, net debt of $14.4 million.
See the LYRA income statement, the LYRA chart for price history, or the LYRA stock overview for the latest quote and news.
LYRA key metrics FAQ
What is Lyra Therapeutics's ROIC?
Lyra Therapeutics's return on invested capital was −541.8% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Lyra Therapeutics have?
Lyra Therapeutics had total debt of $30.3 million at the end of fiscal 2025.
What is Lyra Therapeutics's current ratio?
Lyra Therapeutics's current ratio was 1.71 at the end of fiscal 2025: current assets were 1.71 times current liabilities.